Radar · Orthopedics in California
Best Orthopedics Companies in California, United States
The 212 best Orthopedics companies in California, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Biosplice.
By Riya SenguptaFinancials
212companies tracked
$6.7Bdisclosed funding
1unicorns
111have raised
FLIAR INTELLIGENCE · ORTHOPEDICS × CALIFORNIA
Our analysis of 50 Orthopedics companies
$3.4b in tracked funding; 82% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
82%cloud-native stacks
2025funding peak (by rounds)
2015median founding year
40median Fliar Index™
393kcombined LinkedIn audience
50%of audience held by top 3
1companies hiring publicly (12 mo)
Ranked: Best Orthopedics companies in California
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Biosplice 🦄 Developer of therapeutics modulating alternative splicing for disease treatment | $778M | 62 mo ago | 175 | 2008 | Richard Schwab Co-Founder | — | — |
| 2 | ATEC Spine Developer of treatment solutions for spine disorders | $428M | 65 mo ago | 839 | 1990 | — | — | — |
| 3 | Quince Therapeutics Developer of therapeutics for orthopedic diseases 53Funding top 13%Growth top 37%Tech top 44%Moat top 48% All 8 signals ▾Fundingtop 13% Growthtop 37% Techtop 44% Moattop 48% Talentbottom 49% Marketbottom 37% Newsbottom 37% Globalbottom 37% Funding: Raised $420M across 7 rounds · 7 rounds over 12 yrs (0.6/yr) Growth: Web rank 50,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $420M | 1 mo ago | 21 | 2012 | Dirk Thye CEO | — | — |
| 4 | BioAge Labs Provider of a bioinformatics platform for biomarkers and drug discovery | $294M | 28 mo ago | 43 43 → 100 (+133%) · sector median +74% | — | — | 101 patents NLRP3 inflammasome inhibitors and apelin receptor modulators for BBB, muscle, weight therapies | 1 launch |
| 5 | Relievant Medsystems Developer of medical devices for patients suffering from chronic vertebrogenic low back pain | $273M | 39 mo ago | 9 | 2004 | — | 252 patents Steerable spinal vertebral treatment devices and bone‑access nerve modulation technologies. | — |
| 6 | Moximed Developer of an implant for pre-arthroplasty osteoarthritis patients 53Funding top 18%Moat top 19%Product top 26%Patents top 31% All 11 signals ▾Fundingtop 18% Moattop 19% Producttop 26% Patentstop 31% Innovationtop 34% Growthtop 35% Techbottom 49% Talentbottom 49% Globalbottom 44% Marketbottom 26% Newsbottom 18% Funding: Raised $262M across 7 rounds · 7 rounds over 18 yrs (0.4/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 271 patents rank vs industry peers · Fliar Intelligence Index 53/100 | $262M | 22 mo ago | 15 | 2006 | Josh Makower Founder & Chairman | 271 patents Implantable orthopedic devices for joint load reduction and mechanical energy absorption | — |
| 7 | SetPoint Medical Developer of implantable neuromodulation devices for inflammatory diseases 72Funding top 18%Product top 18%Innovation top 19%Patents top 22% All 10 signals ▾Fundingtop 18% Producttop 18% Innovationtop 19% Patentstop 22% Growthtop 24% Newstop 24% Moattop 26% Techtop 49% Globalbottom 42% Marketbottom 40% Funding: Raised $248M across 11 rounds · 11 rounds over 17 yrs (0.6/yr) Product: 8 distinct product lines · Company stage: Series F rank vs industry peers · Fliar Intelligence Index 72/100 | $248M | 14 mo ago | 46 | 2006 | — | 157 patents Bioelectronic neuromodulation devices targeting vagus nerve for chronic inflammation control | 1 launch · 1 partnership |
| 8 | Rani Therapeutics Developer of technology for the oral delivery of large drug molecules 72Growth top 22%Funding top 23%Patents top 24%Talent top 27% All 11 signals ▾Growthtop 22% Fundingtop 23% Patentstop 24% Talenttop 27% Innovationtop 28% Newstop 30% Moattop 35% Techtop 45% Marketbottom 49% Fin. healthbottom 44% Globalbottom 42% Growth: Revenue +59% YoY · Fresh capital in last 24 mo Funding: Raised $234M across 6 rounds · 6 rounds over 13 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 72/100 | $234M | 7 mo ago | 163 | 2012 | Mir Imran Founder | 456 patents Oral ingestible devices for delivering biologic therapeutics to the gastrointestinal tract | 1 launch |
| 9 | Vertos Medical Developer of minimally invasive treatment for lumbar spinal stenosis | $178M | 36 mo ago | 140 | 2005 | Eric Wichems President & Chief Executive Officer | — | — |
| 10 | Angitia Developer of drugs for muscle, bone, and joint diseases 29Funding top 16%Talent top 38%Moat top 47%Market bottom 40% All 7 signals ▾Fundingtop 16% Talenttop 38% Moattop 47% Marketbottom 40% Globalbottom 39% Innovationbottom 23% Patentsbottom 20% Funding: Raised $156M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 29/100 | $156M | 4 mo ago | — | 2018 | Muyu Li Co-Founder & COO | 4 patents Anti‑sclerostin biologics for osteoporosis and bone‑mass therapies | — |
| 11 | Nevro Provider of high-frequency spinal cord stimulation implants | $154M | 74 mo ago | 1,215 1,215 → 903 (-26%) · sector median +74% | 2006 | Michael DeMane President and Chief Executive Officer | 786 patents Optimized spinal cord neurostimulation devices for pain relief with efficient battery use | 2 launchs · 1 partnership |
| 12 | Benvenue Medical Online slot gaming platform offering diverse games and trusted service | $149M | 125 mo ago | 24 | 2004 | — | 135 patents Minimally invasive spinal interbody fusion devices and graft delivery systems. | — |
| 13 | Zosano Pharma Developer of transdermal drug delivery systems for a broad range of therapeutic indications | $147M | 92 mo ago | 40 | 2006 | — | — | — |
| 14 | Expansion Therapeutics Provider of a software system for the development of drugs | $140M | 56 mo ago | 20 | 2016 | Matthew Disney Co-Founder | — | — |
| 15 | Vertiflex Innovative medical solutions transforming lives through pain management products and technologies | $132M | 110 mo ago | 100 | 2005 | Michael Mahoney CEO | 245 patents Minimally invasive interspinous spinal implants for decompression and stabilization | — |
| 16 | DFine Spine solutions: vertebral compression fracture, tumor ablation, and bone biopsy | $126M | 149 mo ago | 1,903 | 2004 | — | 305 patents Percutaneous tumor ablation devices with parameter-modulated energy delivery | — |
| 17 | Kate Therapeutics Developer of AAV-based gene therapies to treat genetically defined muscle disease | $124M | 25 mo ago | 46 | 2020 | — | — | — |
| 18 | Osteal Therapeutics Developer of pharmaceuticals for musculoskeletal therapeutics to treat orthopedic infections 29Funding top 19%Moat top 38%Talent bottom 49%Global bottom 37% All 5 signals ▾Fundingtop 19% Moattop 38% Talentbottom 49% Globalbottom 37% Marketbottom 31% Funding: Raised $111M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) Moat: Editorial + unicorn rating 5/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 29/100 | $111M | 8 mo ago | 13 | 2013 | David Thompson Chairman and Chief Executive Officer | — | 9 job openings |
| 19 | Spinal Modulation Neurostimulator for treatment of intractable lower limb pain | $104M | 156 mo ago | 76 | 2004 | — | 207 patents Spinal cord stimulation hardware minimizing lead migration and optimizing stimulation parameters. | — |
| 20 | Si-Bone Titanium implant fixation system | $103M | 120 mo ago | 344 344 → 560 (+63%) · sector median +74% | 2008 | Laura Francis Chief Executive Officer | 294 patents Patents concentrated in health & consumer products | 1 launch |
| 21 | Allay Therapeutics Developer of drugs for post-surgical pain management 42Funding top 18%Moat top 39%Market bottom 44%Global bottom 38% All 5 signals ▾Fundingtop 18% Moattop 39% Marketbottom 44% Globalbottom 38% Newsbottom 21% Funding: Raised $102M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 42/100 | $102M | 12 mo ago | 50 | 2017 | — | — | — |
| 22 | Spinal Kinetics Medical technology company providing innovative solutions for musculoskeletal pathologies and spinal care | $100M | 115 mo ago | 67 | 2003 | — | 110 patents Implantable spinal stabilization, intervertebral disc and facet joint prosthetic devices. | — |
| 23 | CARLSMED Developer of devices for spine surgery | $98M | 27 mo ago | 44 | 2018 | Mike Cordonnier Co-Founder & CEO | 224 patents Patents concentrated in health & consumer products | 2 awards |
| 24 | Lineage Cell Therapeutics Developer of cell based therapies for the treatment of cancer, eye disease and spinal disorders | $94M | 25 mo ago | 75 | 1990 | Brian Culley CEO | — | — |
| 25 | Epirium Bio Developer of therapeutic solutions for the treatment of cancer patients | $85M | 78 mo ago | 17 | 2008 | — | — | — |
| 26 | Symic Biomedical Developer of compounds to protect against tissue degradation and promote healing during illness or injury | $84M | 85 mo ago | 2 | 2012 | — | 18 patents Synthetic extracellular‑matrix‑binding peptidoglycan biomaterials for wound and tissue repair | — |
| 27 | Zeda Developer of medical devices to address the needs of the spine device market | $68M | 39 mo ago | 90 | 2017 | Alexis Dang Co-Founder & CMO | — | — |
| 28 | Epicrispr Bio Developer of therapeutics for multiple disease 35Funding top 23%Talent top 38%Moat top 42%Tech bottom 43% All 6 signals ▾Fundingtop 23% Talenttop 38% Moattop 42% Techbottom 43% Globalbottom 37% Marketbottom 32% Funding: Raised $68.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 35/100 | $68M | 14 mo ago | — | 2018 | Lei Qi Founder | — | — |
| 29 | Cytokinetics Developer of muscle activators as potential treatments for debilitating diseases | $60M | 47 mo ago | 423 423 → 780 (+84%) · sector median +74% | 1997 | Robert Blum President & CEO | 1,376 patents Cardiac myosin modulators for heart failure treatment and related small‑molecule synthesis | — |
| 30 | OrthAlign Developer of computer-assisted surgery technology for hip and knee joint replacement | $56M | 69 mo ago | 103 103 → 130 (+26%) · sector median +74% | 2008 | Eric Timko CEO & Chairman | 194 patents Orthopedic surgical navigation and alignment systems for hip and joint replacements | 1 launch · 1 partnership |
| 31 | NuVasive Developer of smart surgical devices for spinal surgery | $54M | 72 mo ago | 2,450 | 1997 | — | 1,915 patents Advanced minimally invasive spinal surgery instruments and fixation devices | — |
| 32 | ClearFlow Provider of an anti-clogging platform for surgical drainage devices 48Funding top 24%Moat top 28%Patents top 30%Growth top 35% All 11 signals ▾Fundingtop 24% Moattop 28% Patentstop 30% Growthtop 35% Talenttop 38% Innovationtop 42% Producttop 43% Techtop 47% Globalbottom 40% Marketbottom 23% Newsbottom 21% Funding: Raised $50.6M across 14 rounds · 14 rounds over 17 yrs (0.8/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 91 patents rank vs industry peers · Fliar Intelligence Index 48/100 | $51M | 10 mo ago | 10 10 → 25 (+150%) · sector median +74% | 2007 | Edward Boyle Founder | 91 patents Medical tube and catheter obstruction removal systems with guide‑wire actuation | 2 launchs |
| 33 | Juvena Therapeutics Company developing protein based therapies for sarcopenia and muscle regeneration 29Funding top 25%Moat top 31%Talent top 38%News bottom 42% All 7 signals ▾Fundingtop 25% Moattop 31% Talenttop 38% Newsbottom 42% Globalbottom 39% Marketbottom 34% Techbottom 28% Funding: Raised $50.0M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 29/100 | $50M | 11 mo ago | 30 | 2017 | Jeremy O'Connell Co-Founder & CSO | — | — |
| 34 | AlterG Provider of hardware and software solutions for rehabilitation | $39M | 56 mo ago | 44 | 2005 | Charles Remsberg CEO | 103 patents Anti‑gravity treadmill and differential pressure systems for rehabilitation and gait training | — |
| 35 | Valitor Developer of therapeutic proteins for multiple disease conditions | $38M | 44 mo ago | 4 | 2010 | — | 47 patents Multivalent peptide/protein–hyaluronic acid conjugate therapeutics for cancer and ocular disease | — |
| 36 | Immunis Developer of cell therapies for age-related and disease-related immune deficits 32Patents top 24%Innovation top 28%Moat top 32%Funding top 39% All 6 signals ▾Patentstop 24% Innovationtop 28% Moattop 32% Fundingtop 39% Globalbottom 40% Marketbottom 21% Patents: 48 patents matched (strict assignee match) · 45 filings since 2022 vs 3 in 2017-21 Innovation: 48 patents (top 32% of patent-holders) · 45 filings since 2022 vs 3 in 2017-21 rank vs industry peers · Fliar Intelligence Index 32/100 | $30M | 17 mo ago | 3 | 2018 | — | 48 patents Prostate cancer liquid biopsy diagnostics using secretome-derived biomarkers | 1 launch |
| 37 | Epica International Provider of robotic CT platforms for healthcare and industrial applications | $26M | 21 mo ago | 22 | 2014 | Joe Soto CEO | — | 1 award |
| 38 | LimiFlex Developer of spinal implants for treating spinal stenosis | $25M | 33 mo ago | 7 | 2008 | Louie Fielding COO and Co-Founder | — | 2 launchs |
| 39 | Osteoboost Provider of a wearable medical device that utilizes targeted mechanical stimulation to deliver patented… 67Tech top 17%Talent top 28%Funding top 34%Growth top 35% All 6 signals ▾Techtop 17% Talenttop 28% Fundingtop 34% Growthtop 35% Globalbottom 48% Marketbottom 40% Tech: 49 technologies across 7/8 capability areas · Cloud: Amazon Cloudfront, Amazon S3 Talent: 4 named leaders on record · 4 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 67/100 | $19M | 2 mo ago | — | 2018 | Nikhil Viswanathan Founder | — | — |
| 40 | SelectION Provider of screening and development platform for drugs 11Funding top 36%Talent bottom 49%Global bottom 37%Market bottom 17% All 4 signals ▾Fundingtop 36% Talentbottom 49% Globalbottom 37% Marketbottom 17% Funding: Raised $15.9M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 11/100 | $16M | 9 mo ago | 2 | 2017 | Andreas Klostermann Founder & CSO | — | — |
| 41 | Aurora Spine Minimally invasive spine and SI joint solutions improving patient lives | $12M | 31 mo ago | 23 23 → 55 (+139%) · sector median +74% | 2012 | Trent Northcutt Founder & CEO | 41 patents Patents concentrated in health & consumer products | — |
| 42 | Tenon Medical Developer of therapy devices for sacroiliac joint dysfunction 40Funding top 33%Growth top 33%News top 35%Tech bottom 49% All 8 signals ▾Fundingtop 33% Growthtop 33% Newstop 35% Techbottom 49% Talentbottom 49% Fin. healthbottom 45% Marketbottom 32% Globalbottom 30% Funding: Raised $11.3M across 5 rounds · 5 rounds over 3 yrs (1.7/yr) Growth: Revenue +20% YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 40/100 | $11M | 3 mo ago | 22 22 → 32 (+45%) · sector median +74% | 2019 | Richard Ginn Founder | — | 1 launch |
| 43 | MAX BioPharma Biopharmaceutical company pioneering Oxysterol Therapeutics® for debilitating and fatal human diseases | $10M | 15 mo ago | 5 | 2010 | Farhad Parhami D President & CEO | — | — |
| 44 | MyoGene Bio Manufacturer of devices for muscular dystrophy treatment 8Talent top 38%Funding top 45%Global bottom 29%Market bottom 10% All 4 signals ▾Talenttop 38% Fundingtop 45% Globalbottom 29% Marketbottom 10% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $3.2M across 6 rounds · 6 rounds over 5 yrs (1.2/yr) rank vs industry peers · Fliar Intelligence Index 8/100 | $3M | 7 mo ago | 3 | 2020 | April Pyle Co-Founder | — | — |
| 45 | Neuromuscular Dynamics Developer of a system quantifying neuromuscular ability for orthopedic rehabilitation | $3M | 20 mo ago | — | 2015 | Francis Cuevas Founder | — | — |
| 46 | Knee Voice Developer of the device for tracking the health of the knee | $2M | 22 mo ago | 7 | 2015 | Carlos Leal Co - Founder | — | — |
| 47 | Meduloc Developer of intramedullary implant for internal fixation of small bones fractures 45Moat top 38%Patents top 44%Talent top 45%Innovation bottom 49% All 6 signals ▾Moattop 38% Patentstop 44% Talenttop 45% Innovationbottom 49% Fundingbottom 48% Globalbottom 33% Moat: Editorial + unicorn rating 5/10 · IP moat: 19 patents Patents: 19 patents matched (strict assignee match) · 10 filings since 2022 vs 9 in 2017-21 rank vs industry peers · Fliar Intelligence Index 45/100 | $2M | 4 mo ago | — | 2016 | Joshua Hustedt Co-Founder | 19 patents Orthopedic bone fixation implants such as plates, screws, and intramedullary nails. | 1 launch · 1 partnership |
| 48 | Hippos Exoskeleton Developer of wearable airbag technology designed for knee joint protection | $642K | 19 mo ago | — | 2024 | Kylin Shaw Co-Founder & CEO | 2 patents Sensor‑enabled wearable knee orthotics for active joint support and monitoring | — |
| 49 | BioDynamik Developer of medical devices restoring perfusion in limbs | $570K | 14 mo ago | — | 2024 | Shanbao Cheng Co-Founder & CTO | 13 patents Patents concentrated in health & consumer products | — |
| 50 | Dorian Therapeutics Developer of therapies for aging diseases | $150K | 13 mo ago | 9 | 2018 | — | — | 1 award |
Top 12 Orthopedics companies in California
#1
Public · San Francisco, California · founded 2012 · 21 employees$420.1Mraised▾
Public · San Francisco, California · founded 2012 · 21 employees
Developer of therapeutics for orthopedic diseases. It offers a lead candidate NOV004 which is an anabolic peptide engineered to target and concentrate at the bone fracture site and also helps in spinal fusion and osteogenesis Imperfecta.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 13%Growth
top 37%Tech
top 44%Moat
top 48%Talent
bottom 49%Market
bottom 37%Funding: Raised $420M across 7 rounds · 7 rounds over 12 yrs (0.6/yr) · Last round Post IPO (May 2026)
Growth: Web rank 50,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo
Tech: 37 technologies across 3/8 capability areas · Cloud: Amazon Web Services, Cloudflare · Security: Cloudflare Bot Management, Hsts
Audience (LinkedIn): 4k LinkedIn followers
Activity (LinkedIn): 1 product launches · 1 partnerships (incl. LifeSci Capital) announced in 12 mo
Funding rounds
- May 2026Post IPO$187M
- Feb 2020Post IPO$125M
- May 2018Series B$84.5M
- Feb 2017Series A$7.6M
Founders & team
Investors
Breakout Labs, Dolby Family Ventures, Takeda, Pfizer Venture Investments, Takeda Ventures, Sequoia Capital
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAmazon Web Services
#2
Series D · Woodland Hills, California · founded 2018$156Mraised▾
Series D · Woodland Hills, California · founded 2018
Developer of drugs for muscle, bone, and joint diseases. The company's products include AGAO1 for bone fusion, AGA02 for rare diseases, AGA03 for regeneration, AGA04 for osteoporosis, AGA05 for healing, and others. Also, developed many drugs for multiple disease treatments such as nonunion of fractures, osteoarthritis, rare diseases of skeletal muscle, and mineral metabolism diseases caused by diseases or disorders of endocrine organs.
Fliar Intelligence Index™ 29how this company ranks against its industry peers
Funding
top 16%Talent
top 38%Moat
top 47%Market
bottom 40%Global
bottom 39%Innovation
bottom 23%Funding: Raised $156M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) · Last round Series D (Feb 2026)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 5/10 · IP moat: 4 patents · 10 curated direct competitors tracked
Audience (LinkedIn): 4k LinkedIn followers
Funding rounds
- Feb 2026Series D$130M
- Dec 2024Series C$120M
- Jan 2024Series B$40M
- Oct 2023Series B$46M
Founders & team
Investors
Hillhouse, TF Capital, Yonghua Capital, Global Sources, Guangzhou Hi-Tech Communication Technology, Guangdong Capital
#3
Public · San Jose, California · founded 2012 · 163 employees$234.1Mraised▾
Public · San Jose, California · founded 2012 · 163 employees
Developer of technology for the oral delivery of large drug molecules. The company has a proprietary platform is capable of delivering a wide range of biologics for the treatment of various chronic diseases. The company develops RaniPill capsule has broad applications for the treatment of acromegaly, rheumatoid arthritis, psoriatic arthritis, growth hormone deficiency, osteoporosis, Crohn’s disease, hemophilia, diabetes, among other diseases.
Fliar Intelligence Index™ 72how this company ranks against its industry peers
Growth
top 22%Funding
top 23%Patents
top 24%Talent
top 27%Innovation
top 28%News
top 30%Growth: Revenue +59% YoY · Fresh capital in last 24 mo
Funding: Raised $234M across 6 rounds · 6 rounds over 13 yrs (0.5/yr) · Last round Post IPO (Oct 2025)
Patents: 456 patents matched (strict assignee match) · 180 filings since 2022 vs 204 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 6k LinkedIn followers
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Oct 2025Post IPO$60.3M
- Dec 2020Series E$69M
- Nov 2020Series E$50M
- Feb 2018Series E$53M
Founders & team
Investors
GeneScience Pharmaceuticals, Shire, Cathay Financial Holdings, Google Ventures, Novartis, AstraZeneca
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai
#4
Series D · San Clemente, California · founded 2013 · 13 employees$110.8Mraised▾
Series D · San Clemente, California · founded 2013 · 13 employees
Developer of pharmaceuticals for musculoskeletal therapeutics to treat orthopedic infections. The company lead product VT-X7 is for Periprosthetic joint infection and targets chronic bacterial PJI. Another drug candidate A-103 is for fungal PJI. The company offers its drug-device combination product for antibiotic therapy for local delivery to treat infected joint prostheses like bacterial and fungal infections for joints like shoulder, knee, and hip.
Fliar Intelligence Index™ 29how this company ranks against its industry peers
Funding
top 19%Moat
top 38%Talent
bottom 49%Global
bottom 37%Market
bottom 31%Funding: Raised $111M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) · Last round Series D (Oct 2025)
Moat: Editorial + unicorn rating 5/10 · Soonicorn
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 4k LinkedIn followers
Hiring (LinkedIn): 9 hiring posts in 12 mo (public) · momentum +9 · hiring: Area Vice President (East/West), Account Manager
Funding rounds
- Oct 2025Series D$15.6M
- May 2024Series D$50M
- Sep 2023Series C$23M
- Mar 2022Series B$30M
Founders & team
Investors
Gideon Strategic Partners, Johnson & Johnson Innovation – JJDC, Prism Ventures, Medvest Capital, HM Venture Partners, Huimei Capital
#5
Series A · San Francisco, California · founded 2018$18.7Mraised▾
Series A · San Francisco, California · founded 2018
Provider of a wearable medical device that utilizes targeted mechanical stimulation to deliver patented therapy for low bone density. The device offers a non-pharmacological treatment option for postmenopausal women with osteopenia that provides precise vibrations to the lumbar spine and hips to reduce bone strength and density decline.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Tech
top 17%Talent
top 28%Funding
top 34%Growth
top 35%Global
bottom 48%Market
bottom 40%Tech: 49 technologies across 7/8 capability areas · Cloud: Amazon Cloudfront, Amazon S3 · Devops: Nginx
Talent: 4 named leaders on record · 4 C-suite/founder profiles curated
Funding: Raised $18.7M across 5 rounds · 5 rounds over 8 yrs (0.6/yr) · Last round Series A (Apr 2026)
Funding rounds
- Apr 2026Series A$8M
- Mar 2023Series A$5M
- May 2021Seed$2.5M
- Aug 2019Seed$505K
Founders & team
Investors
Good Growth Capital, Ambit Health Ventures, Portfolia, Golden Seeds, Berkeley Angel Network, Reno Seed Fund
Tech stack
Amazon CloudfrontAmazon S3Amazon Web ServicesAmplitudeApolloApplovin
#6
Series F · Santa Clarita, California · founded 2006 · 46 employees$248.2Mraised▾
Series F · Santa Clarita, California · founded 2006 · 46 employees
Developer of implantable neuromodulation devices for inflammatory diseases. It offers the SetPoint System which is a a small, wireless, implantable device that stimulates the vagus nerve activating the body’s innate pathways to reduce inflammation and restore immunologic balance.
Fliar Intelligence Index™ 72how this company ranks against its industry peers
Funding
top 18%Product
top 18%Innovation
top 19%Patents
top 22%Growth
top 24%News
top 24%Funding: Raised $248M across 11 rounds · 11 rounds over 17 yrs (0.6/yr) · Last round Series F (Mar 2025)
Product: 8 distinct product lines · Company stage: Series F
Innovation: 157 patents (top 13% of patent-holders) · 68 filings since 2022 vs 45 in 2017-21 · 8 product lines
Audience (LinkedIn): 13k LinkedIn followers — 3.3% of this cohort's audience
Activity (LinkedIn): 1 product launches · 1 partnerships (incl. Word Center) announced in 12 mo
Funding rounds
- Mar 2025Series F$140M
- Jan 2023Series E$80M
- Jan 2023Venture Debt—
- Jul 2021Conventional Debt$35M
Investors
Runway Growth Capital, New Enterprise Associates, Viking Global Investors, Gilmartin Capital, Action Potential Venture Capital, Boston Scientific
Tech stack
Amazon Web ServicesAnimate.CssApple Icloud MailAutomatic.CssBricksCloudflare
#7
Public · Los Gatos, California · founded 2019 · 22 employees$11.3Mraised▾
Public · Los Gatos, California · founded 2019 · 22 employees
Developer of therapy devices for sacroiliac joint dysfunction
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 33%Growth
top 33%News
top 35%Tech
bottom 49%Talent
bottom 49%Fin. health
bottom 45%Funding: Raised $11.3M across 5 rounds · 5 rounds over 3 yrs (1.7/yr) · Last round Post IPO (Mar 2026)
Growth: Revenue +20% YoY · Fresh capital in last 24 mo
News: 9 BI events in 12 mo (of 23 tracked, 5 types) · -10% YoY · 1 high-value events (IPO/M&A/funding/contracts) in 12 mo
Audience (LinkedIn): 2k LinkedIn followers
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Mar 2026Post IPO$4.3M
- Nov 2025Post IPO$2.9M
- Feb 2024Post IPO$2.6M
- Nov 2023Post IPO$1.2M
Founders & team
#8
Series D · Menlo Park, California · founded 2017 · 50 employees$101.9Mraised▾
Series D · Menlo Park, California · founded 2017 · 50 employees
Developer of drugs for post-surgical pain management. The company's proprietary technology platform combines non-opioid analgesics and biopolymers to create dissolvable candidates that deliver pain relief within a targeted site. The company's lead candidate is ATX-101 for post surgical knee rehabilitation. Other candidates include ATX-201 and ATX-301 injectables for on-demand delivery.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 18%Moat
top 39%Market
bottom 44%Global
bottom 38%News
bottom 21%Funding: Raised $102M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Venture Debt (Jun 2025)
Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked
Market: 50 employees
Audience (LinkedIn): 4k LinkedIn followers
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Jun 2025Venture Debt—
- Jan 2025Series D$57.5M
- Dec 2022Series D—
- Sep 2021Series C$86.9M
Investors
Arboretum Ventures, New Enterprise Associates, Temasek, Pavilion Capital Partners, Vertex Ventures HC, Vertex Growth
#9
Series D · Irvine, California · founded 2007 · 10 employees$50.6Mraised▾
Series D · Irvine, California · founded 2007 · 10 employees
Provider of an anti-clogging platform for surgical drainage devices. The technology that utilizes a magnetically driven Clearance Loop to proactively maintain blood flow to allow evacuation of blood and fluids from the chest cavity thus preventing Retained Blood syndrome. Retained Blood Syndrome (RBS) is the composite of drainage-related complications after cardiothoracic surgery, including hemothorax, pericardial tamponade, bloody pleural or pericardial effusions.It is used to resolve catheter clogging in multiple medical market segments, including urinary catheters, gastrointestinal catheters, and wound drainage.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Funding
top 24%Moat
top 28%Patents
top 30%Growth
top 35%Talent
top 38%Innovation
top 42%Funding: Raised $50.6M across 14 rounds · 14 rounds over 17 yrs (0.8/yr) · Last round Series D (Jul 2025)
Moat: Editorial + unicorn rating 8/10 · IP moat: 91 patents · Soonicorn
Patents: 91 patents matched (strict assignee match) · 31 filings since 2022 vs 38 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 3k LinkedIn followers
Activity (LinkedIn): 2 product launches announced in 12 mo
Funding rounds
- Jul 2025Series D$2.1M
- Jun 2024Series D$2.3M
- Aug 2020Series D$7.5M
- May 2019Series D$7.6M
Founders & team
Investors
Oregon Venture Fund, Aphelion Capital, California Technology Ventures, RCT, Octane, Global Cardiovascular Innovation Center
Tech stack
Apache Http ServerCart FunctionalityCdnjsCloudflareCloudflare Bot ManagementCore-Js
#10
Series B · San Mateo, California · founded 2017 · 30 employees$50Mraised▾
Series B · San Mateo, California · founded 2017 · 30 employees
Juvena Therapeutics is engaged in the development of protein-based therapeutics that promote tissue generation in the elderly. The company has developed a discovery platform for screening restored muscle function which can be developed to other tissue types. The company has developed a protein cocktail which can improve the ability of aged muscle to heal and regenerate and also to look youthful and active.
Fliar Intelligence Index™ 29how this company ranks against its industry peers
Funding
top 25%Moat
top 31%Talent
top 38%News
bottom 42%Global
bottom 39%Market
bottom 34%Funding: Raised $50.0M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) · Last round Series B (Jun 2025)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 10k LinkedIn followers — 2.7% of this cohort's audience
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Jun 2025Series B$41M
- Nov 2022Series A$41M
- Sep 2021Grant (prize money)$254.3K
- Feb 2018Series A$4.3M
Founders & team
Investors
Mubadala, Horizons Ventures, Bison Ventures, Manta Ray Ventures, Iron Grey, Alumni Ventures
#11
Series D · Hayward, California · founded 2006 · 15 employees$262.3Mraised▾
Series D · Hayward, California · founded 2006 · 15 employees
Developer of an implant for pre-arthroplasty osteoarthritis patients. The lead product, the KineSpring Knee Implant System, is designed for patients with knee osteoarthritis. It's a partial load absorber that reduces knee joint load by up to 13 kg.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 18%Moat
top 19%Product
top 26%Patents
top 31%Innovation
top 34%Growth
top 35%Funding: Raised $262M across 7 rounds · 7 rounds over 18 yrs (0.4/yr) · Last round Series D (Aug 2024)
Moat: Editorial + unicorn rating 8/10 · IP moat: 271 patents · Soonicorn
Product: 3 distinct product lines · Company stage: Series D
Audience (LinkedIn): 19k LinkedIn followers — 4.8% of this cohort's audience
Funding rounds
- Aug 2024Series D$62.7M
- Aug 2022Series C$40M
- Aug 2022Conventional Debt—
- Mar 2017Series C$50M
Founders & team
Investors
Advent Life Sciences, Future Fund, New Enterprise Associates, Morgenthaler, Gilde Healthcare, GBS
Tech stack
Apple Icloud MailCloudflareCloudflare Bot ManagementCookieyesGoogle AnalyticsGoogle Tag Manager
#12
Series A · San Diego, California · founded 2017 · 2 employees$15.9Mraised▾
Series A · San Diego, California · founded 2017 · 2 employees
selectION provides screening and development platform for drugs. The company provides ion channel blockers by targeting additional potassium, sodium, calcium, and chloride channels, which will lead to other clinical applications in pain management and oncology. The company uses peptide structures derived from evolutionary tuned toxins from venomous animals like scorpions or cone snails as blueprints for its screening platform.
Fliar Intelligence Index™ 11how this company ranks against its industry peers
Funding
top 36%Talent
bottom 49%Global
bottom 37%Market
bottom 17%Funding: Raised $15.9M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) · Last round Series A (Sep 2025)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Global: Legal entities in 2 countries: Germany, United States
Funding rounds
- Sep 2025Series A$20M
- Jun 2023Series A$11.8M
- May 2019Series A$4.1M
Founders & team
Investors
SDL Ventures, Global Source Ventures
Funding & investor landscape
$6.7Btotal disclosed funding
122companies funded
504disclosed rounds
2rounds last 90 days
Most active investors
New Enterprise Associates7 rounds
Notable founders
Dirk Thye
CEO · Quince Therapeutics
Muyu Li
Co-Founder & COO · Angitia
Hua Ke
Co-Founder & CEO · Angitia
Mir Imran
Founder · Rani Therapeutics
Talat Imran
CEO · Rani Therapeutics
David Thompson
Chairman and Chief Executive Officer · Osteal Therapeutics
Nikhil Viswanathan
Founder · Osteoboost
Daniel Burnett
Founder & CEO · Osteoboost
Richard Ginn
Founder · Tenon Medical
Edward Boyle
Founder · ClearFlow
Hannah Beathard
Chief Executive Officer · ClearFlow
Jeremy O'Connell
Co-Founder & CSO · Juvena Therapeutics
Prism market signals · United States · country-scoped Prism corpus, 517,506 docs
Market landscape — 10 sub-themes by coverage
Share of Orthopedics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth flat
RESEARCH IN CALIFORNIA · Health & Bio
How research on Medical Devices in California is moving
A read on the academic research around Medical Devices in California — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 110 papers.
UC San Francisco, Berkeley, and USC lead California's medical-device research, predominantly exploring soft robotics and surgical simulation with a cautiously optimistic tone amid balanced breakthrough and concern findings.
110 papers · stance +0.32 · 29% breakthrough · 35% concern
top institutions
- University of California, San Francisco20
- University of California, Berkeley14
- University of Southern California13
- University of California San Diego12
- University of California, Los Angeles10
leading researchers
Joseph S. Ross · Sanket S. Dhruva · Florian Richter · Michael C. Yip · Rita F. Redberg · Jacob Rosén
prism intelligence · tone & topics
85% positive · 13% critical tone
HealthcareHealthBusinessMedical TechnologyRoboticsEducation
▲
Breakthroughs29 · 26%
▼ 30%→18% share
▼0.6× share momentum5 median citations41% since 2021mostly methods-led
Surgical-robot breakthroughs are cooling — Breakthroughs field-share dropped 30%→18% despite Robot (15) and Surgical robot (11) leading counts.
rising sub-themes (early→recent)
- Robot15
- Surgical robot11
- Robotics6
- Computer vision6
- Biomedical engineering3
Landmark Degradation and antibacterial properties of magnesium alloys in artificial urine for potential resorbable ureteral stent · 153 cites
◆
Advancements35 · 32%
▲ 22%→35% share
▲1.6× share momentum2 median citations66% since 2021mostly methods-led
Surgical-robot advancement research is intensifying — Advancements field-share rose 22%→35%, with Teleoperation newly emerging at 3 papers.
rising sub-themes (early→recent)
- Biomedical engineering1→3
- Robot2→4
- Surgical robot3→5
Newly emergingTeleoperation 0→3 · MEDLINE 0→3
Landmark Subdermal Flexible Solar Cell Arrays for Powering Medical Electronic Implants · 142 cites
▼
Concerns35 · 32%
▼ 48%→32% share
▼0.7× share momentum3 median citations60% since 2021mostly position pieces
FDA-related concerns are intensifying — Food and Drug Administration papers surged 1→6, with Adverse effect newly emerging alongside Patient safety doubling.
rising sub-themes (early→recent)
- Food and drug administration1→6
- Patient safety1→3
Newly emergingAdverse effect 0→3
Landmark Many-body–localized discrete time crystal with a programmable spin-based quantum simulator · 186 cites
Common questions
How many Orthopedics companies are there in California, United States?
Radar tracks 212 indexable Orthopedics companies headquartered in California, United States that meet our profile-completeness bar.
What is the total funding raised by Orthopedics companies in California, United States?
The Orthopedics companies in California, United States on this list have raised a combined $6.7B in disclosed equity funding across 122 funded companies.
Which is the highest-funded Orthopedics company in California, United States?
Biosplice is the highest-funded Orthopedics company in California, United States, with $778M in disclosed equity funding.
How many Orthopedics companies in California, United States are funded?
122 of the 212 Orthopedics companies in California, United States on this list have disclosed at least one equity funding round.
How many Orthopedics unicorns are there in California, United States?
1 Orthopedics company in California, United States on this list is valued at $1B or more.
Who are the top investors in California, United States Orthopedics companies?
The most active investors in California, United States Orthopedics companies on this list include HHS, New Enterprise Associates, Johnson & Johnson Innovation – JJDC, National Science Foundation, Three Arch Partners.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.